Ozempic Gastroparesis Settlement Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Specific Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. This broad educational heritage, encompassing topics from disease prevention to therapeutic interventions, provides a necessary context for evaluating emerging health concerns. Within this framework, the transition from general health literacy to specific product exposure considerations becomes a natural progression. As public awareness of pharmaceutical interventions grows, attention increasingly turns to the real-world implications of medication use, including potential adverse effects that may arise during treatment. The shift from abstract health education to concrete exposure scenarios is particularly relevant when examining widely prescribed medications such as Ozempic. This glucagon-like peptide-1 receptor agonist, originally developed for glycemic control in type 2 diabetes, has seen expanded use for weight management. With its widespread adoption, questions have emerged regarding the relationship between Ozempic exposure and gastrointestinal complications, specifically gastroparesis—a condition characterized by delayed gastric emptying. The occupational exposure concern here is not limited to healthcare workers handling the drug, but extends to patients who are exposed to the medication as part of their treatment regimen. Understanding the criteria for potential settlements related to Ozempic-associated gastroparesis requires careful examination of exposure patterns, duration of use, and documented gastrointestinal symptoms, all within the broader context of pharmaceutical risk assessment.

Understanding Ozempic and Its Mechanism of Action

Ozempic (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, its use has been associated with gastrointestinal adverse reactions, including conditions such as gastroparesis, which is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis presents clinically with symptoms including nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, and it can lead to significant nutritional deficiencies, weight loss, and impaired quality of life. The pharmacological mechanism linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract, and activation of these receptors slows gastric emptying, reduces gastric acid secretion, and modulates intestinal motility. While this effect is intended to improve glycemic control by delaying nutrient absorption, it can also cause or exacerbate delayed gastric emptying, leading to symptoms consistent with gastroparesis.

Clinical Trial Evidence of Gastrointestinal Adverse Reactions

In clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) compared to Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse effects, which may include gastroparesis-like symptoms.

Adequacy of Warnings and Labeling

Regarding the adequacy of warnings, the prescribing information for Ozempic includes gastrointestinal adverse reactions in the label, but it does not specifically list gastroparesis as a distinct adverse reaction. The label notes that Ozempic has not been studied in patients with a history of pancreatitis and recommends considering other antidiabetic therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may be relevant for patients who develop this condition after exposure. The timeline between exposure and documented harm is variable. In clinical trials, gastrointestinal adverse reactions were most common during dose escalation, suggesting that symptoms can emerge early in treatment. However, gastroparesis may develop or become clinically apparent after prolonged use, and the condition can persist even after discontinuation of the drug.

Settlement Criteria for Ozempic-Associated Gastroparesis

For patients affected by Ozempic-associated gastroparesis, settlement-related considerations may include the need to establish a causal link between the drug and the harm. Key factors in such cases include the timing of symptom onset relative to Ozempic initiation, the absence of other causes of gastroparesis (such as diabetes-related autonomic neuropathy, prior surgery, or idiopathic causes), and the severity and duration of symptoms. Documentation of gastroparesis diagnosis through objective testing, such as gastric emptying studies, is critical. Additionally, the adequacy of informed consent and warnings provided by healthcare providers may be examined. Patients who experienced severe or persistent gastrointestinal symptoms that led to emergency department visits, hospitalizations, or long-term disability may have stronger claims. The settlement criteria for Ozempic gastroparesis cases are likely to consider the strength of the medical evidence linking the drug to the condition, the severity of harm, and the degree to which the manufacturer's warnings were sufficient to alert prescribers and patients to the risk. In summary, Ozempic is associated with a range of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis, through its mechanism of delaying gastric emptying. Clinical trial data show a dose-dependent increase in gastrointestinal adverse events, with higher rates of discontinuation due to these effects compared to placebo. The label does not specifically warn about gastroparesis, which may be relevant for patients who develop this condition. Settlement considerations for affected patients will depend on establishing a temporal and causal relationship between Ozempic use and the development of gastroparesis, as well as the adequacy of warnings provided.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can lead to symptoms consistent with gastroparesis, such as nausea, vomiting, and bloating. Clinical trials show a dose-dependent increase in gastrointestinal adverse reactions, including conditions like gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic gastroparesis claims?

Settlement criteria typically require establishing a causal link between Ozempic use and gastroparesis, including timing of symptom onset, exclusion of other causes, objective diagnosis (e.g., gastric emptying study), and severity of harm. The adequacy of warnings provided by the manufacturer may also be considered.

Does the Ozempic label warn about gastroparesis?

The prescribing information for Ozempic includes gastrointestinal adverse reactions but does not specifically list gastroparesis as a distinct adverse reaction. This absence may be relevant for patients who develop the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.